QURE · uniQure N.V. · Insider Trading
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-11-06 | Meek David D. |
Director |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
The shares were sold pursuant to a sales plan adopted by the Reporting Person on May 26, 2026 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. |
Ordinary Shares
|
9,080 |
| 2026-10-30 | Abi-Saab Walid |
Chief Medical Officer |
Award↑
Filing footnotes — Ordinary Shares (Direct)
Represents performance-based restricted share units ("PRSUs") granted to the Reporting Person on January 20, 2026 under the Issuer's 2014 Share Incentive Plan, as amended and restated, which were earned on October 30, 2026 as the result of the satisfaction of certain regulatory milestones. Each PRSU represents the contingent right to receive one Ordinary Share. These shares will vest on the later of (i) 10 business days after the receipt of certain regulatory clearance and (ii) January 20, 2027, subject to the Reporting Person's continued employment by the Issuer through such vesting date. |
Ordinary Shares
|
18,750 |
| 2026-07-02 | Kapusta Matthew C |
Director, CEO, Managing Director |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on October 5, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $44.10 to $44.80. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Ordinary Shares
|
9,200 |
| 2026-07-02 | Kapusta Matthew C |
Director, CEO, Managing Director |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on October 5, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.48 to $46.10. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Ordinary Shares
|
7,600 |
| 2026-07-02 | Kapusta Matthew C |
Director, CEO, Managing Director |
Convert↑
Filing footnotes — Ordinary Shares (Direct)
The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on October 5, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. |
Ordinary Shares
|
21,082 |
| 2026-07-02 | Kapusta Matthew C |
Director, CEO, Managing Director |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on October 5, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. The Stock Option vested in full on January 26, 2022. |
Stock Option (Right to Buy)
|
21,082 |
| 2026-07-02 | Kapusta Matthew C |
Director, CEO, Managing Director |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on October 5, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.00 to $45.95. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Ordinary Shares
|
4,282 |
| 2026-06-30 | Kaye Jack |
Director |
Convert↑
Filing footnotes — Ordinary Shares (Direct)
The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on June 16, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. |
Ordinary Shares
|
4,107 |
| 2026-06-30 | Kaye Jack |
Director |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on June 16, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. The Stock Option vested in full on June 13, 2024. |
Stock Option (Right to Buy)
|
17,060 |
| 2026-06-30 | Abi-Saab Walid |
Chief Medical Officer |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on September 26, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. The Stock Option was granted on March 1, 2024 and vested 25% on the first anniversary of the date of grant, and vests 6.25% quarterly thereafter until fully vested. |
Stock Option (Right to Buy)
|
10,000 |
| 2026-06-30 | Kaye Jack |
Director |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on June 16, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.19 to $46.88. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote. |
Ordinary Shares
|
4,107 |
| 2026-06-30 | Kaye Jack |
Director |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on June 16, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.19 to $46.80. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote |
Ordinary Shares
|
17,060 |
| 2026-06-30 | Abi-Saab Walid |
Chief Medical Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on September 26, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.19 to $46.97. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote. |
Ordinary Shares
|
10,000 |
| 2026-06-30 | Kaye Jack |
Director |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on June 16, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. The Stock Option vested in full on February 25, 2022. |
Stock Option (Right to Buy)
|
4,107 |
| 2026-06-30 | Kaye Jack |
Director |
Convert↑
Filing footnotes — Ordinary Shares (Direct)
The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on June 16, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. |
Ordinary Shares
|
17,060 |
| 2026-06-30 | Abi-Saab Walid |
Chief Medical Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on September 26, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.24 to $46.80. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote. |
Ordinary Shares
|
20,000 |
| 2026-06-30 | Abi-Saab Walid |
Chief Medical Officer |
Convert↑
Filing footnotes — Ordinary Shares (Direct)
The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on September 26, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. |
Ordinary Shares
|
10,000 |
| 2026-06-26 | Abi-Saab Walid |
Chief Medical Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.69 to $46.96. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Ordinary Shares
|
1,434 |
| 2026-06-25 | Kapusta Matthew C |
Director, CEO, Managing Director |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on October 5, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. The Stock Option vested in full on January 25, 2023. |
Stock Option (Right to Buy)
|
28,716 |
| 2026-06-25 | Kapusta Matthew C |
Director, CEO, Managing Director |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on October 5, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.30. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Ordinary Shares
|
28,716 |
| 2026-06-25 | Kapusta Matthew C |
Director, CEO, Managing Director |
Convert↑
Filing footnotes — Ordinary Shares (Direct)
The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on October 5, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. |
Ordinary Shares
|
28,716 |
| 2026-06-24 | Kapusta Matthew C |
Director, CEO, Managing Director |
Convert↑
Filing footnotes — Ordinary Shares (Direct)
The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on October 5, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. |
Ordinary Shares
|
4,128 |
| 2026-06-24 | Kapusta Matthew C |
Director, CEO, Managing Director |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on October 5, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. The Stock Option vested in full on January 25, 2023. |
Stock Option (Right to Buy)
|
4,128 |
| 2026-06-24 | Kapusta Matthew C |
Director, CEO, Managing Director |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on October 5, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. |
Ordinary Shares
|
6,696 |
| 2026-06-18 | Kapusta Matthew C |
Director, CEO, Managing Director |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on October 5, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.03. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Ordinary Shares
|
4,656 |
| 2026-06-18 | Kapusta Matthew C |
Director, CEO, Managing Director |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on October 5, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.01. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Ordinary Shares
|
37,015 |
| 2026-06-18 | Kapusta Matthew C |
Director, CEO, Managing Director |
Convert↑
Filing footnotes — Ordinary Shares (Direct)
The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on October 5, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. |
Ordinary Shares
|
4,656 |
| 2026-06-18 | Kapusta Matthew C |
Director, CEO, Managing Director |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on October 5, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. The Stock Option vested in full on January 25, 2023. |
Stock Option (Right to Buy)
|
4,656 |
| 2026-06-17 | Kapusta Matthew C |
Director, CEO, Managing Director |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on October 5, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $43.56 to $43.94. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Ordinary Shares
|
6,023 |
| 2026-06-17 | Kapusta Matthew C |
Director, CEO, Managing Director |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on October 5, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. |
Ordinary Shares
|
11,585 |
| 2026-06-17 | Balachandran Madhavan |
Director |
Convert↑
Filing footnotes — Ordinary Shares (Direct)
The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on March 10, 2026 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. |
Ordinary Shares
|
5,295 |
| 2026-06-17 | Balachandran Madhavan |
Director |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on March 10, 2026 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. The Stock Option vested in full on January 25, 2020. |
Stock Option (Right to Buy)
|
5,295 |
| 2026-06-17 | Balachandran Madhavan |
Director |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on March 10, 2026 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.50 to $42.93. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote. |
Ordinary Shares
|
1,690 |
| 2026-06-17 | Kapusta Matthew C |
Director, CEO, Managing Director |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on October 5, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.00 to $45.17. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Ordinary Shares
|
33,334 |
| 2026-06-17 | Kapusta Matthew C |
Director, CEO, Managing Director |
Convert↑
Filing footnotes — Ordinary Shares (Direct)
The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on October 5, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. |
Ordinary Shares
|
62,581 |
| 2026-06-17 | Kapusta Matthew C |
Director, CEO, Managing Director |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on October 5, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.00 to $45.02. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Ordinary Shares
|
32,581 |
| 2026-06-17 | Kapusta Matthew C |
Director, CEO, Managing Director |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on October 5, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. |
Ordinary Shares
|
56,929 |
| 2026-06-17 | Kapusta Matthew C |
Director, CEO, Managing Director |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on October 5, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.50 to $43.48. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Ordinary Shares
|
23,977 |
| 2026-06-17 | Balachandran Madhavan |
Director |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on March 10, 2026 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $47.00 to $47.36. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote. |
Ordinary Shares
|
5,295 |
| 2026-06-17 | Balachandran Madhavan |
Director |
Convert↑
Filing footnotes — Ordinary Shares (Direct)
The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on March 10, 2026 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. |
Ordinary Shares
|
6,390 |
| 2026-06-17 | Kaye Jack |
Director |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on June 16, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.50 to $42.83. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote. |
Ordinary Shares
|
5,295 |
| 2026-06-17 | Balachandran Madhavan |
Director |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on March 10, 2026 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $43.12 to $43.95. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote. |
Ordinary Shares
|
4,700 |
| 2026-06-17 | Kaye Jack |
Director |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on June 16, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. The Stock Option vested in full on January 25, 2020. |
Stock Option (Right to Buy)
|
5,295 |
| 2026-06-17 | Kaye Jack |
Director |
Convert↑
Filing footnotes — Ordinary Shares (Direct)
The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on June 16, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. |
Ordinary Shares
|
5,295 |
| 2026-06-17 | Kapusta Matthew C |
Director, CEO, Managing Director |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on October 5, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. The Stock Option vested in full on January 26, 2022. |
Stock Option (Right to Buy)
|
62,581 |
| 2026-06-17 | Balachandran Madhavan |
Director |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on March 10, 2026 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. The Stock Option vested in full on January 26, 2019. |
Stock Option (Right to Buy)
|
6,390 |
| 2026-06-15 | Potts Jeannette |
Chief Legal Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.62 to $27.78. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Ordinary Shares
|
5,237 |
| 2026-06-15 | Balachandran Madhavan |
Director |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on March 10, 2026 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.58 to $28.05. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote. |
Ordinary Shares
|
10,000 |
| 2026-06-15 | Balachandran Madhavan |
Director |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on March 10, 2026 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. The Stock Option vested in full on September 20, 2021. |
Stock Option (Right to Buy)
|
10,000 |
| 2026-06-15 | Balachandran Madhavan |
Director |
Convert↑
Filing footnotes — Ordinary Shares (Direct)
The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on March 10, 2026 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. |
Ordinary Shares
|
10,000 |